CALMARE THERAPEUTICS INCORPORATED (OTCMKTS:CTTC) Files An 8-K Entry into a Material Definitive Agreement

CALMARE THERAPEUTICS INCORPORATED (OTCMKTS:CTTC) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

On June 1, 2020, Calmare Therapeutics Incorporated (the “Registrant”) was awarded Federal Supply Schedule Contract 36F79720D0118 (the “Agreement”), effective June 15, 2020, by the U.S. Department of Veterans Affairs (the “VA”). The Agreement authorizes $2,500,000 of orders by the VA for Calmare® Pain Therapy Devices. The Agreement was awarded under Schedule 65 II A-Medical. Equipment and Supplies under Federal Supply Schedule Solicitation RFP-797-FSS-99-0025-R9 and has a term of 5 years. A redacted copy of the award letter is provided in this Form 8-K as Exhibit 10.1.

On June 9, 2020, the Registrant issued a press release titled “Calmare Therapeutics Awarded $2.5 Million, Five-Year Contract by U.S. Department of Veteran Affairs for Calmare® Pain Therapy Devices”. A copy of the press release is provided in this Form 8-K as Exhibit 99.1.

The information in Item 8.01 of this Form 8-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in Item 8.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

Exhibits.

10.1 Letter, dated June 1, 2020, from U.S. Federal Supply Schedule Service to Calmare Therapeutics Incorporated awarding Federal Supply Schedule Contract 36F79720D0118, effective June 15, 2020, by the U.S. Department of Veterans Affairs to Calmare Therapeutics Incorporated.
99.1 Press Release, dated June 9, 2020, titled “Calmare Therapeutics Awarded $2.5 Million, Five-Year Contract by U.S. Department of Veteran Affairs for Calmare® Pain Therapy Devices”.


CALMARE THERAPEUTICS Inc Exhibit
EX-10.1 2 ea122850ex10-1_calmaretherap.htm LETTER,…
To view the full exhibit click here

Story continues below

About CALMARE THERAPEUTICS INCORPORATED (OTCMKTS:CTTC)

Calmare Therapeutics Incorporated (CTI) is a medical device company. The Company is engaged in developing and commercializing products and technologies for chronic neuropathic pain and wound care affliction patients. The Company’s medical device, the Calmare Pain Therapy Device (the Calmare Device), is a non-invasive and non-addictive modality that can treat chronic, neuropathic pain. The Company offers a portfolio of technologies in life, electronic, nano and physical sciences. The Company’s technology portfolio includes CALMARE pain therapy treatment, neuroprotection and cognitive enhancement, sexual dysfunction therapeutic, skin pigment enhancer, wound sealant, preparation of ordered multi-layer films, silica thin films, structural steel fissure detection paint, public key encryption, growing single crystals, and video compression and moving picture experts group (MPEG)-4. The Company’s subsidiary is Vector Vision, Inc.

An ad to help with our costs